Difference between revisions of "Effect of development of health care system in emerging market countries to existing pharmaceutical industry"
Jump to navigation
Jump to search
(2 intermediate revisions by the same user not shown) | |||
Line 13: | Line 13: | ||
==Inhibitors:== | ==Inhibitors:== | ||
Giant pharmaceutical corporations in emgerging markets | |||
De-globalization | |||
==Paradigms:== | ==Paradigms:== | ||
Well being vs. Treating the sick | |||
==Experts:== | ==Experts:== | ||
WHO | |||
==Timing:== | ==Timing:== | ||
Dates for key milestones in the development of the driving force. | Dates for key milestones in the development of the driving force. | ||
==Web Resources:== | ==Web Resources:== | ||
Useful resources on the web relating to this force. | Useful resources on the web relating to this force. |
Latest revision as of 20:09, 16 September 2009
This page is under construction and edited by Susan Liu EMBA09. In case of any questions/remarks, feel free to contact me
Description:
Generic durgs will be mainstream. Western pharmaceutical companies no longer can hold on to their patent with current business model.
Enablers:
WHO
India medical development
Inhibitors:
Giant pharmaceutical corporations in emgerging markets
De-globalization
Paradigms:
Well being vs. Treating the sick
Experts:
WHO
Timing:
Dates for key milestones in the development of the driving force.
Web Resources:
Useful resources on the web relating to this force.